COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2023 and June 30, 2022 is as follows (in thousands):


Six Months Ended June 30, 2023	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates, Inc. (FN 2)				Location in Financial Statements
	Short-term		Long-term			Long-term		Long-term		Short-term		Long-term
Balance as of January 1, 2023	$	2,845	$	10,050		$	230	$	3,700	$	—	$	57,607
Transfers	—		—			—		—		12,500		(12,500)
Change in fair value of contingent consideration liabilities	1,544		1,537		Research and development	—		(2,200)		200		5,000		Selling, general and administrative
Balance as of June 30, 2023	4,389		11,587			230		1,500		12,700		50,107


Six Months Ended June 30, 2022	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc.				Location in Financial Statements
	Short-term		Long-term			Long-term		Short-term		Long-term
Balance as of January 1, 2022	$	3,691	$	11,408		$	230	$	—	$	21,800

Transfers	—		—			—		4,885		(4,885)
Change in fair value of contingent consideration liabilities	(155)		(1,978)		Research and development	—		(4,885)		1,219		Selling, general and administrative
Balance as of June 30, 2022	$	3,536	$	9,430		$	230	$	—	$	18,134